1.8 小结
对CRC 的分子分型的研究逐渐深入，使临床有希望更有效地改善mCRC 患者的管理与治疗模式。 随着科学技术的发展，如ctDNA 等允许无创进行分子评估的技术日益成熟，生物标志物的整合有望成为更重要的临床决策信息来源，并将进一步改善患者的生存。
（孙晶、贾宏涛）
参考文献
[1]KARAPETIS C S,KHAMBATA-FORD S,JONKER D J,et al.K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].The New England journal of medicine,2008,359(17): 1757-1765.
[2]BARDELLI A,SIENA S.Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer [J].J Clin Oncol,2010,28(7): 1254-1261.
[3]DOUILLARD J Y,SIENA S,CASSIDY J,et al.Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer [J].Annals of oncology : official journal of the European Society for Medical Oncology,2014,25(7): 1346-1355.
[4]INNOCENTI F,OU F S,QU X,et al.Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome [J].J Clin Oncol,2019,37(14): 1217-1227.
[5]CERCEK A,BRAGHIROLI M I,CHOU J F,et al.Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations [J].Clinical cancer research : an official journal of the American Association for Cancer Research,2017,23(16): 4753-4760.
[6]VENOOK A P,NIEDZWIECKI D,INNOCENTI F,et al.Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance) [J].2016,34(15 suppl): 3504.
[7]ARNOLD D,LUEZA B,DOUILLARD J Y,et al.Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials [J].Annals of oncology : official journal of the European Society for Medical Oncology,2017,28(8): 1713-1729.
[8]HOLCH J W,RICARD I,STINTZING S,et al.The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials [J].Eur J Cancer,2017,70:87-98.
[9]ABRAHAO A B K,KARIM S,COLWELL B,et al.The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement [J].Current oncology (Toronto,Ont),2017,24(6): 390-400.
[10]CREMOLINI C,ROSSINI D,DELL'AQUILA E,et al.Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial [J].JAMA Oncol,2019,5(3): 343-350.
[11]ROSKOSKI R,JR.RAF protein-serine/threonine kinases: structure and regulation [J].Biochem Biophys Res Commun,2010,399(3): 313-317.
[12]CANCER GENOME ATLAS N.Comprehensive molecular characterization of human colon and rectal cancer [J].Nature,2012,487(7407): 330-337.
[13]LOREE J M,DOWERS A,TU D,et al.Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial [J].2019,37(4 suppl): 537.
[14]UMAR A,BOLAND C R,TERDIMAN J P,et al.Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability [J].J Natl Cancer Inst,2004,96(4): 261-268.(https://www.daowen.com)
[15]LINDOR N M,BURGART L J,LEONTOVICH O,et al.Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors [J].J Clin Oncol,2002,20(4): 1043-1048.
[16]ADVANI S M,ADVANI P,DESANTIS S M,et al.Clinical,Pathological,and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis [J].Translational oncology,2018,11(5): 1188-1201.
[17]NOWAK J A,YURGELUN M B,BRUCE J L,et al.Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing [J].J Mol Diagn,2017,19(1): 84-91.
[18]KOOPMAN M,KORTMAN G A,MEKENKAMP L,et al.Deficient mismatch repair system in patients with sporadic advanced colorectal cancer [J].Br J Cancer,2009,100(2): 266-273.
[19]VENDERBOSCH S,NAGTEGAAL I D,MAUGHAN T S,et al.Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO,CAIRO2,COIN and FOCUS studies [J].Clinical cancer research : an official journal of the American Association for Cancer Research,2014,20(20): 5322-5330.
[20]OVERMAN M J,LONARDI S,WONG K Y M,et al.Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer [J].J Clin Oncol,2018,36(8): 773-779.
[21]KHEDER E S,HONG D S.Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins [J].Clinical cancer research : an official journal of the American Association for Cancer Research,2018,24(23): 5807-5814.
[22]SARTORE-BIANCHI A,AMATU A,BONAZZINA E,et al.Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience [J].Target Oncol,2017,12(4): 525-533.
[23]PIETRANTONIO F,DI NICOLANTONIO F,SCHROCK A B,et al.ALK,ROS1,and NTRK Rearrangements in Metastatic Colorectal Cancer [J].J Natl Cancer Inst,2017,109(12).
[24]REESER J W,MARTIN D,MIYA J,et al.Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors [J].J Mol Diagn,2017,19(5): 682-696.
[25]WANG Z,GERSTEIN M,SNYDER M.RNA-Seq: a revolutionary tool for transcriptomics [J].Nat Rev Genet,2009,10(1): 57-63.
[26]DRILON A,LAETSCH T W,KUMMAR S,et al.Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children [J].The New England journal of medicine,2018,378(8): 731-739.
[27]DEMETRI G D,PAZ-ARES L,FARAGO A F,et al.LBA17 - Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2,STARTRK-1 and ALKA-372-001 [J].Annals of Oncology,2018,29(viii): 713.
[28]HYMAN D,KUMMAR S,FARAGO A,et al.Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954),a selective next-generation TRK inhibitor (TRKi) [J].2019,79(13 supple): CT127.
[29]GUINNEY J,DIENSTMANN R,WANG X,et al.The consensus molecular subtypes of colorectal cancer [J].Nature medicine,2015,21(11): 1350-1356.
[30]ESTRELLA J S,TETZLAFF M T,BASSETT R L,et al.Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing [J].Molecular cancer therapeutics,2015,14(12): 2887-2895.